Navigation Links
GeneraMedix, Inc. Announces Sale of Innovative Epoprostenol Formulation to Actelion Ltd.
Date:2/23/2009

LIBERTY CORNER, N.J., Feb. 23 /PRNewswire/ -- GeneraMedix, Inc. announced today that it has entered into a definitive agreement to sell its improved formulation of epoprostenol sodium for the intravenous treatment of pulmonary arterial hypertension (PAH) to Actelion LTD., a biopharmaceutical company with its headquarters in Allschwil/Basel, Switzerland. Financial terms of the deal were not disclosed.

"This sale speaks directly to our company's ongoing commitment to serving the unique needs of patients in specialty markets, in this case pulmonary arterial hypertension (PAH)," said Ron Quadrel, CEO, of GeneraMedix, Inc. "I'm also very pleased to conclude this transaction with Actelion, a company that is committed to improving the lives of PAH patients through improved treatment options," added Quadrel.

On June 27, 2008, the U.S. FDA approved Epoprostenol for Injection (1.5 mg/ml vial) for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.

The new formulation of epoprostenol uses non-proprietary diluents, and once reconstituted prior to use, it may be stored for up to 48 hours at 25 degrees Celsius or for five days in the refrigerator at 2-8 degrees Celsius. Global patents have been filed for this new formulation. Actelion will be responsible for global development, registration and commercialization for the product.

"We are very pleased to acquire this innovative product as it builds on our commitment to PAH therapy. Actelion has always led the drive in developing innovative therapies for PAH patients and treating physicians, and we believe this new improved formulation could potentially play a significant role in the management of PAH," stated Jean-Paul Clozel, M.D. and CEO of Actelion.'/>"/>

SOURCE GeneraMedix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Schering-Plough Announces Collaboration With World Health Organization to Provide Access to Pandemic Influenza Vaccine Technology to Developing Countries
2. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period
3. Abbott Announces 11 Percent Increase in Quarterly Dividend
4. Shire Announces Opening of Office in Japan
5. InterMune Announces Issuance of U.S. Patent for ITMN-191
6. Lightwave Logic, Inc. Announces the Addition of Anthony J. Cocuzza, PhD to its Technology Team
7. Psychemedics Corporation Announces 2008 Year End Results
8. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
9. Amicus Therapeutics Announces Change to Board of Directors
10. Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2008 Earnings Release Conference Call Webcast
11. Obio Pharmaceutical Announces Product Growth Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... CA (PRWEB) November 21, 2014 Why ... that makes Albert Einstein so instantly recognizable? Why have ... physicist, mathematician, astronomer and author Hilton Ratcliffe seeks out ... have nothing at all to do with science. In ... Harbor Publishing , November 21, 2014), Ratcliffe puts it ...
(Date:11/21/2014)... , Nov. 20, 2014 /CNW/ - Aequus ... to announce that it has closed a brokered ... warrants for approximately C$3.7 million.  Cormark Securities Inc. ... in the Brokered Offering for a syndicate of ... PI Financial Corp. (collectively the "Agents"). Concurrently with ...
(Date:11/18/2014)... FL (PRWEB) November 17, 2014 ... point-of-care diagnostic tests – today announces its third ... and Prevention’s (CDC) Get Smart About Antibiotics Week ... Week is a national campaign designed to highlight ... health departments, and non-profit and for-profit partners to ...
(Date:11/18/2014)... 18, 2014 Alanda Software, a ... Reporting solutions, announced today that a top tier ... Consummate Provider™ solution in both the U.S. and ... SaaS based, Data Quality remediation portal, designed to ... party Providers improve their ability to capture, transmit ...
Breaking Biology Technology:“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2
... of hazardous waste resulting from the nations nuclear weapons ... state called Hanford. Beneath this desert landscape about ... of tons of chemicals are captured within the stratified ... flow paths. These paths create uncertainties about where ...
... the National Nanotechnology Initiative has just been released by ... of the National Science and Technology Councils Committee on ... (NNCO). The 2007 NNI Strategic Plan describes ... ensure that the United States derives growing economic benefits ...
... Pharmos Corporation,(Nasdaq: PARS ) announced today that ... placement of its 10% Convertible Debentures due November ... principal amount of the,Debentures, at par, and received ... purchasers consisted of certain existing investors in the ...
Cached Biology Technology:Where does stored nuclear waste go? 2National Nanotechnology Initiative releases new strategic plan 2National Nanotechnology Initiative releases new strategic plan 3Pharmos Corporation Completes Initial Closing of Private Placement 2
(Date:11/6/2014)... 2014 - Insilico Medicine, Inc, a Baltimore-based bioinformatics ... related diseases announced a research collaboration with the ... Oncology, Inc (OTC: CSBR). , "There are many ... but Champions Oncology,s TumorGraft technology is unique in ... regimen experimentally generating vast amounts of valuable data. ...
(Date:11/5/2014)... in their ability to identify scents and odors. ... perceptual evaluation of odors, with women outperforming men on ... differences in olfactory detection may play a role in ... perception of smell, which is naturally linked to associated ... suggested to be cognitive or emotional, rather than perceptual. ...
(Date:11/4/2014)... Medicine announced today that it is a Grand ... Bill & Melinda Gates Foundation. Laura Goetzl, ... Sciences; and Vice Chair of Research and Academic ... pursue an innovative global health and development research ... Neurodevelopment.", Grand Challenges Explorations (GCE) funds individuals worldwide ...
Breaking Biology News(10 mins):Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2The female nose always knows: Do women have more olfactory neurons? 2Temple University School of Medicine receives Grand Challenges Explorations grant 2
... RIVERSIDE, Calif. Four researchers at the University of California, ... the Advancement of Science ( AAAS ). Including this year,s ... have been recognized with AAAS Fellow distinction is 194. ... members by their peers. This year AAAS gave this honor ...
... risk of attack has led to the development of ... larval stage. One caterpillar may look like a stick, ... may have its advantages, University of Florida researchers uncovered ... another strategy previously best-known in adult butterflies: mimicry. ...
... , The Ontario Genomics Institute (OGI) has awarded two ... leading-edge technologies to better aid the work of Ontario ... Applied Genomics (TCAG), part of The Hospital for Sick ... and Technology Innovation Centre, and StemCore Laboratories based at ...
Cached Biology News:4 UC Riverside researchers receive national recognition 2Caterpillars mimic one another for survival 2Caterpillars mimic one another for survival 32 research facilities awarded technology seeding grants 2
Mouse monoclonal antibody raised against a full length recombinant YARS. NCBI Entrez Gene ID = YARS...
... DS-L2 imaging controller is a successor of ... allows users to comfortably observe, record and ... features an 8.4 inch LCD (XGA) monitor ... Nikon cameras including the DS-Fi1 , DS-5Mc ...
... NovaTaq DNA Polymerase is a premium ... polymerase. This thermostable enzyme is suitable for ... ensure the highest purity and reproducible performance, ... variety of quality control assays. NovaTaq DNA ...
Mouse polyclonal antibody raised against a partial recombinant TSEN2. NCBI Entrez Gene ID = 80746...
Biology Products: